QQQ   432.23 (+0.27%)
AAPL   169.56 (-1.81%)
MSFT   416.66 (+0.73%)
META   502.49 (+0.45%)
GOOGL   154.93 (+0.05%)
AMZN   184.08 (+0.25%)
TSLA   157.09 (-2.72%)
NVDA   876.46 (+1.91%)
AMD   163.77 (+2.15%)
NIO   3.84 (-1.29%)
BABA   70.02 (-0.85%)
T   16.04 (-1.23%)
F   12.21 (-0.16%)
MU   121.46 (+0.07%)
GE   155.81 (+1.37%)
CGC   6.86 (-1.72%)
DIS   114.23 (+1.13%)
AMC   2.80 (+13.36%)
PFE   25.80 (-0.42%)
PYPL   63.98 (+0.74%)
XOM   118.71 (-0.81%)
QQQ   432.23 (+0.27%)
AAPL   169.56 (-1.81%)
MSFT   416.66 (+0.73%)
META   502.49 (+0.45%)
GOOGL   154.93 (+0.05%)
AMZN   184.08 (+0.25%)
TSLA   157.09 (-2.72%)
NVDA   876.46 (+1.91%)
AMD   163.77 (+2.15%)
NIO   3.84 (-1.29%)
BABA   70.02 (-0.85%)
T   16.04 (-1.23%)
F   12.21 (-0.16%)
MU   121.46 (+0.07%)
GE   155.81 (+1.37%)
CGC   6.86 (-1.72%)
DIS   114.23 (+1.13%)
AMC   2.80 (+13.36%)
PFE   25.80 (-0.42%)
PYPL   63.98 (+0.74%)
XOM   118.71 (-0.81%)
QQQ   432.23 (+0.27%)
AAPL   169.56 (-1.81%)
MSFT   416.66 (+0.73%)
META   502.49 (+0.45%)
GOOGL   154.93 (+0.05%)
AMZN   184.08 (+0.25%)
TSLA   157.09 (-2.72%)
NVDA   876.46 (+1.91%)
AMD   163.77 (+2.15%)
NIO   3.84 (-1.29%)
BABA   70.02 (-0.85%)
T   16.04 (-1.23%)
F   12.21 (-0.16%)
MU   121.46 (+0.07%)
GE   155.81 (+1.37%)
CGC   6.86 (-1.72%)
DIS   114.23 (+1.13%)
AMC   2.80 (+13.36%)
PFE   25.80 (-0.42%)
PYPL   63.98 (+0.74%)
XOM   118.71 (-0.81%)
QQQ   432.23 (+0.27%)
AAPL   169.56 (-1.81%)
MSFT   416.66 (+0.73%)
META   502.49 (+0.45%)
GOOGL   154.93 (+0.05%)
AMZN   184.08 (+0.25%)
TSLA   157.09 (-2.72%)
NVDA   876.46 (+1.91%)
AMD   163.77 (+2.15%)
NIO   3.84 (-1.29%)
BABA   70.02 (-0.85%)
T   16.04 (-1.23%)
F   12.21 (-0.16%)
MU   121.46 (+0.07%)
GE   155.81 (+1.37%)
CGC   6.86 (-1.72%)
DIS   114.23 (+1.13%)
AMC   2.80 (+13.36%)
PFE   25.80 (-0.42%)
PYPL   63.98 (+0.74%)
XOM   118.71 (-0.81%)

MultiPlan (MPLN) Competitors

$0.72
-0.05 (-6.17%)
(As of 01:25 PM ET)

MPLN vs. AMWL, AUGX, PHR, PETQ, AUNA, IRMD, PAHC, ABUS, NGNE, and FULC

Should you be buying MultiPlan stock or one of its competitors? The main competitors of MultiPlan include American Well (AMWL), Augmedix (AUGX), Phreesia (PHR), PetIQ (PETQ), Auna (AUNA), Iradimed (IRMD), Phibro Animal Health (PAHC), Arbutus Biopharma (ABUS), Neurogene (NGNE), and Fulcrum Therapeutics (FULC). These companies are all part of the "medical" sector.

MultiPlan vs.

American Well (NYSE:AMWL) and MultiPlan (NYSE:MPLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, community ranking, profitability, analyst recommendations, valuation and dividends.

56.1% of American Well shares are owned by institutional investors. Comparatively, 87.2% of MultiPlan shares are owned by institutional investors. 12.9% of American Well shares are owned by insiders. Comparatively, 8.2% of MultiPlan shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

American Well received 22 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 48.48% of users gave American Well an outperform vote while only 41.67% of users gave MultiPlan an outperform vote.

CompanyUnderperformOutperform
American WellOutperform Votes
32
48.48%
Underperform Votes
34
51.52%
MultiPlanOutperform Votes
10
41.67%
Underperform Votes
14
58.33%

In the previous week, American Well had 6 more articles in the media than MultiPlan. MarketBeat recorded 8 mentions for American Well and 2 mentions for MultiPlan. American Well's average media sentiment score of 0.53 beat MultiPlan's score of 0.39 indicating that MultiPlan is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
American Well
2 Very Positive mention(s)
4 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MultiPlan
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

American Well currently has a consensus target price of $1.00, suggesting a potential upside of 87.44%. MultiPlan has a consensus target price of $2.00, suggesting a potential upside of 174.91%. Given American Well's higher probable upside, analysts plainly believe MultiPlan is more favorable than American Well.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
American Well
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
MultiPlan
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

MultiPlan has higher revenue and earnings than American Well. MultiPlan is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Well$259.05M0.60-$675.16M-$2.40-0.22
MultiPlan$961.52M0.48-$91.70M-$0.15-4.82

MultiPlan has a net margin of -9.54% compared to MultiPlan's net margin of -260.63%. American Well's return on equity of -8.31% beat MultiPlan's return on equity.

Company Net Margins Return on Equity Return on Assets
American Well-260.63% -40.19% -33.28%
MultiPlan -9.54%-8.31%-2.05%

American Well has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, MultiPlan has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Summary

MultiPlan beats American Well on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MPLN vs. The Competition

MetricMultiPlanBusiness services IndustryMedical SectorNYSE Exchange
Market Cap$465.56M$16.06B$4.73B$17.09B
Dividend YieldN/A3.39%5.45%3.58%
P/E Ratio-4.8215.72194.4821.98
Price / Sales0.483.122,531.8210.11
Price / Cash1.7622.7833.3315.26
Price / Book0.275.264.704.96
Net Income-$91.70M$392.85M$100.13M$964.87M
7 Day Performance-12.87%-5.29%-4.69%-5.08%
1 Month Performance1.83%-2.93%-3.43%-2.20%
1 Year Performance-34.32%5.67%12.49%76.38%

MultiPlan Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMWL
American Well
2.2616 of 5 stars
$0.72
flat
$1.75
+142.9%
-73.1%$208.43M$259.05M-0.301,104Analyst Report
News Coverage
Gap Up
AUGX
Augmedix
2.4264 of 5 stars
$4.06
+1.0%
$5.17
+27.3%
N/A$197.88M$44.85M-9.021,430Short Interest ↑
PHR
Phreesia
4.3976 of 5 stars
$23.74
+3.7%
$31.62
+33.2%
-28.0%$1.34B$356.30M-9.421,438
PETQ
PetIQ
3.259 of 5 stars
$18.16
-0.4%
$29.00
+59.7%
+38.4%$534.45M$1.10B302.721,933
AUNA
Auna
0 of 5 stars
$7.25
-9.4%
N/AN/A$535.92MN/A0.0014,958Analyst Report
News Coverage
Gap Up
IRMD
Iradimed
4.9038 of 5 stars
$42.00
-0.7%
$60.00
+42.9%
+3.6%$531.72M$65.56M30.88148Positive News
PAHC
Phibro Animal Health
4.4913 of 5 stars
$13.12
+1.9%
$15.33
+16.9%
-15.8%$531.36M$977.90M36.441,920Short Interest ↓
ABUS
Arbutus Biopharma
2.062 of 5 stars
$3.01
-2.6%
$4.33
+44.2%
+3.5%$539.37M$18.14M-6.8373Short Interest ↑
Positive News
NGNE
Neurogene
1.1756 of 5 stars
$40.96
-1.6%
$49.00
+19.6%
N/A$526.34MN/A-3.2991
FULC
Fulcrum Therapeutics
2.9955 of 5 stars
$8.45
flat
$13.17
+55.8%
+205.4%$523.39M$2.81M-5.3576Short Interest ↓

Related Companies and Tools

This page (NYSE:MPLN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners